CAMBRIDGE, Mass. — ConcertAI said it is expanding its CancerLinQ Suite with new AI-driven capabilities designed to help oncologists identify clinical trial candidates faster and access patient insights within existing clinical workflows.
The Cambridge-based real-world healthcare intelligence company said it is unveiling the enhancements at the 2026 American Society of Clinical Oncology Annual Meeting. The updates are intended to support clinical trial matching and treatment decisions by using AI to analyze structured and unstructured data on a weekly basis.
ConcertAI said its proprietary dataset includes more than 13 million patient records across all 50 states, providing a real-world evidence resource for quality benchmarking and clinical research. The company said the CancerLinQ Suite combines quality governance, clinical decision support and trial optimization into one platform.
“The promise of technology in oncology isn’t measured by how sophisticated the platform is, but instead by whether it meaningfully supports the clinicians delivering care and positively impacts patient outcomes,” said Shaalan Beg, M.D., Chief Medical Officer, Oncology, ConcertAI. “Our newest CancerLinQ enhancements were built to put trial matching and real-world cohort comparisons directly in the workflow, where they can actually inform treatment decisions. That’s the standard we hold ourselves to: AI that earns its place at the bedside.”
The company said the TriaLinQ module within CancerLinQ now includes patient eligibility matching tools powered by AI models that assess clinical trial eligibility factors such as line of therapy, disease progression, recurrence and biomarker profiles.
ConcertAI said the platform can screen eligible patients 3.3 times faster than traditional manual methods. The company said integrating those insights into clinical workflows can support up to 50% higher clinical trial enrollment, potentially expanding patient access to investigational therapies.
The CancerLinQ Suite’s PatientLinQ module is designed to provide a fuller view of patient care, with an emphasis on biomarker insights. ConcertAI said the module can identify clinical trials where patients have a 90% or greater likelihood of eligibility and align those options with specific clinical contexts.
The company said PatientLinQ also allows clinicians to compare individual patients with real-world cohorts drawn from its dataset, evaluate treatment patterns and outcomes, identify gaps in testing or treatment delivery and support faster treatment decisions.
ConcertAI said the suite is powered by Cara, its proprietary agentic AI platform, which curates unstructured clinical data into explainable insights trained for oncology use cases. The company said TriaLinQ and PatientLinQ build on the broader CancerLinQ Suite, which draws longitudinal oncology data from more than 900 sites of care.
